Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacific Edge Limited (PFGTF)
OTHER OTC:PFGTF
Pacific Edge Limited (PFGTF) Stock Price & Analysis
3 Followers
PFGTF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.02 - $0.13
Previous Close$0.05
Volume3.60K
Average Volume (3M)2.95K
Market Cap
$40.49M
Enterprise Value-$26.44M
Total Cash (Recent Filing)$113.41M
Total Debt (Recent Filing)$2.07M
Price to Earnings (P/E)―
Beta-4.73
Next Earnings
Nov 21, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding811,271,344
10 Day Avg. Volume20
30 Day Avg. Volume2,950
Standard Deviation0.92
R-Squared0.02
Alpha0.25
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Pacific Edge Limited News
PremiumCompany Announcements
Pacific Edge Sets Director Nomination Deadline
PremiumCompany Announcements
Pacific Edge Seeks Quotation for New SharesPremiumCompany Announcements
Pacific Edge Issues New Employee Incentive SecuritiesPremiumCompany Announcements
Pacific Edge Maintains Steady Test Volumes
PremiumCompany Announcements
Pacific Edge Options Cease Due to ConditionsPremiumCompany Announcements
Pacific Edge Showcases Year of Growth and Transparency
PremiumCompany Announcements
FirstCape Group Announces Major Stake in Pacific Edge
PremiumCompany Announcements
Pacific Edge Stakeholder Jarden Securities ExitsOptions Prices
Currently, No data available
---
Ownership Overview
2.43% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
97.57% Public Companies and
Individual Investors
PFGTF FAQ
What was Pacific Edge Limited’s price range in the past 12 months?
Pacific Edge Limited lowest stock price was $0.02 and its highest was $0.13 in the past 12 months.
What is Pacific Edge Limited’s market cap?
Currently, no data Available
When is Pacific Edge Limited’s upcoming earnings report date?
Pacific Edge Limited’s upcoming earnings report date is Nov 21, 2024 which is in 122 days.
How were Pacific Edge Limited’s earnings last quarter?
Pacific Edge Limited released its earnings results on May 20, 2024. The company reported -$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.011.
Is Pacific Edge Limited overvalued?
According to Wall Street analysts Pacific Edge Limited’s price is currently Overvalued.
Does Pacific Edge Limited pay dividends?
Pacific Edge Limited does not currently pay dividends.
What is Pacific Edge Limited’s EPS estimate?
Pacific Edge Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pacific Edge Limited have?
Pacific Edge Limited has 811,915,950 shares outstanding.
What happened to Pacific Edge Limited’s price movement after its last earnings report?
Pacific Edge Limited reported an EPS of -$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pacific Edge Limited?
Currently, no hedge funds are holding shares in PFGTF
---
Pacific Edge Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.40%
12-Months-Change
Fundamentals
Return on Equity
-42.63%
Trailing 12-Months
Asset Growth
-31.17%
Trailing 12-Months
Company Description
Pacific Edge Limited
Pacific Edge Ltd. engages in the discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring of cancer. It operates in the Commercial and Research segments. The Commercial segment involves the sales, marketing, laboratory, and support to run the commercial businesses worldwide. The Research segment engages in the research and development of diagnostic and prognostic products for human cancer. The company was founded on February 27, 2001 and is headquartered in Dunedin, New Zealand.
---
Technical Analysis
---